title: Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.
abstract: Artificial antigen-presenting cells are expected to stimulate the expansion and acquisition of optimal therapeutic features of T cells before infusion. Here CD32 that binds to a crystallizable fragment of IgG monoclonal antibody was genetically expressed on human K562 leukemia cells to provide a ligand for T-cell receptor. CD86 and 4-1BBL, which are ligands of co-stimulating receptors of CD28 and 4-1BB, respectively, were also expressed on K562 cells. Then we accomplished the artificial antigen-presenting cells by coupling K32/CD86/4-1BBL cell with OKT3 monoclonal antibody against CD3, named K32/CD86/4-1BBL/OKT3 cells. These artificial modified cells had the abilities of inducing CD8+ T cell activation, promoting CD8+ T cell proliferation, division, and long-term growth, inhibiting CD8+ T cell apoptosis, and enhancing CD8+ T cell secretion of IFN-gamma and perforin. Furthermore, antigen-specific cytotoxic T lymphocytes could be retained in the culture stimulated with K32/CD86/4-1BBL/OKT3 cells at least within 28 days. This approach was robust, simple, reproducible and economical for expansion and activation of CD8+ T cells and may have important therapeutic implications for adoptive immunotherapy.
authors.affiliation: Department of Immunology, School of Medicine, Yangzhou University, Yangzhou 225001, China. gwj1974@263.net
authors.forename: Weijuan
authors.initials: W
authors.lastname: Gong
authors.forename: Mingchun
authors.initials: M
authors.lastname: Ji
authors.forename: Zhengfeng
authors.initials: Z
authors.lastname: Cao
authors.forename: Liheng
authors.initials: L
authors.lastname: Wang
authors.forename: Yayun
authors.initials: Y
authors.lastname: Qian
authors.forename: Maozhi
authors.initials: M
authors.lastname: Hu
authors.forename: Li
authors.initials: L
authors.lastname: Qian
authors.forename: Xingyuan
authors.initials: X
authors.lastname: Pan
mesh_terms: D053330:4-1BB Ligand / Q000276:immunology / Q000378:metabolism*; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism; D017209:Apoptosis; D051940:B7-2 Antigen / Q000276:immunology / Q000378:metabolism*; D018106:CD28 Antigens / Q000276:immunology / Q000378:metabolism*; D017252:CD3 Complex / Q000276:immunology / Q000378:metabolism*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D049109:Cell Proliferation; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D020014:K562 Cells; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation; D054353:Perforin / Q000096:biosynthesis / Q000276:immunology; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology / Q000378:metabolism*
chemical_list: D053330:4-1BB Ligand; D051940:B7-2 Antigen; D018106:CD28 Antigens; D017252:CD3 Complex; C505714:TNFRSF9 protein, human; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D054353:Perforin; D007371:Interferon-gamma